Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy, Safety and Economic Benefits of Topical Wound Oxygen Therapy in the Treatment of Chronic Diabetic Foot Ulcers (TWO2DFU)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02326337
Recruitment Status : Active, not recruiting
First Posted : December 29, 2014
Last Update Posted : February 22, 2018
Sponsor:
Information provided by (Responsible Party):
AOTI Ltd.

Brief Summary:
The purpose of this study is to evaluate the efficacy, safety and economical benefits of Cyclical Pressure Topical Wound Oxygen (TWO2) Therapy in the treatment of chronic diabetic foot ulcers. Subjects will wear a standardized off-loading device and use advanced moist wound therapy (AMWT) dressings. Following a 2 week run-in period with the standardized care and after meeting all the eligibility criteria, half the subjects will use the TWO2 device, while the other half will use a sham device.

Condition or disease Intervention/treatment Phase
Diabetic Foot Ulcer Device: TWO2 Device Device: Placebo Device Not Applicable

Detailed Description:

Subjects meeting the initial eligibility criteria will enter a 2 week run-in period with a standardized off-loading device, advanced moist wound therapy (AMWT) dressings and will receive sharp debridement. Subjects with wounds that do not decrease more than 30% at the end of the 2 week run-in period and where all other eligibility criteria are met, will be randomized to either the TWO2 device arm, or sham (placebo) device arm.

All subjects will use the TWO2/Sham device for 90 minutes a day at their home or nursing care facility 5 times a week for the treatment phase of up to 12 weeks. Monitoring of the wound will take place with weekly clinic visits for safety and compliance assessment and documentation. Weekly wound photographs and measurements will be taken. Wounds that close at, or before, 12 weeks will continue to use TWO2/sham device, off-loading and AMWT and have an additional visit two weeks later to confirm wound closure. All subjects whether healed or not will enter a follow up period of an additional 12 and 38 weeks.

The maximum duration for participation in the trial is 54 weeks. During the follow-up phase, subjects will receive standard care according to the clinician's recommendation and will be asked not to participate in another wound care trial during this period.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 73 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Group Sequential Design of a maximum of 220 subjects with two predetermined interim analyses at 73 and 146 subjects
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multi-national, Multi-center, Prospective, Randomized, Double Blinded, Placebo-controlled Trial to Evaluate the Efficacy of HyperBox Cyclical Topical Wound Oxygen Therapy (TWO2) in the Treatment of Chronic Diabetic Foot Ulcers
Study Start Date : October 2014
Actual Primary Completion Date : February 5, 2018
Estimated Study Completion Date : December 15, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Topical Wound Oxygen Device

Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with Advanced Moist Wound Therapy (AMWT) dressings.

Other Names:

  • Topical Wound Oxygen Therapy
  • TWO2
Device: TWO2 Device
Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
Other Name: TWO2 Therapy

Placebo Comparator: Placebo Device
Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
Device: Placebo Device
Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
Other Name: Sham Device, Control Device




Primary Outcome Measures :
  1. Wound closure within 12 weeks with the use of Topical Wound Oxygen Therapy (TWO2) [ Time Frame: 12 weeks ]
    Incidence of complete wound closure defined as 100% skin re-epithelialization without dressing requirements which is confirmed by 2 consecutive study visits 2 weeks apart.


Secondary Outcome Measures :
  1. Time to complete wound closure [ Time Frame: 54 weeks ]
    Wounds not closed at the end of the12 week treatment phase are assessed for 100% skin re-epithelialization without dressing requirements at a study visit or by telephone call and review of medical record after a further 12 and 26 weeks .

  2. Change in wound size over time [ Time Frame: 54 weeks ]
    Wound size will be documented at study visits by the use of digital photography and wound-mapping software.

  3. Incidence of recurrence [ Time Frame: 54 weeks ]
    Wounds that are documented as closed will be assessed for recurrence at a study visit or by telephone call and review of medical records at 12 and 26 weeks after the treatment phase.

  4. Incidence of amputation [ Time Frame: 54 weeks ]
    Incidence of amputation will be documented throughout the study

  5. Incidence of adverse device effects [ Time Frame: 54 weeks ]
    Incidence of adverse device effects will be documented throughout the study

  6. Quality of Life Assessment [ Time Frame: 54 weeks ]
    Quality of Life is a composite outcome measure assessed by the use of a Visual Analogue Scale to document level of pain and the Cardiff Wound Impact Schedule questionnaire.

  7. Economic Analysis [ Time Frame: 54 weeks ]
    Economic Analysis is a composite measure of the wound before the study (up to one year) and for the duration of the study. The assessment is obtained by documenting treatment history of the wound that includes types of dressings used, time taken for dressing changes, by whom dressings are changed, and type and duration of hospitalization as well as the administration of the EQ-5D questionnaire at the Baseline visit, weeks 4, 8 and 12 on treatment and 12 and 26 weeks post treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 89 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject has a documented diagnosis of Diabetes mellitus Type 1 or 2
  • Foot ulcer at or below ankle with duration of more than 4 weeks but no longer than 1 year
  • If the index ulcer is a post amputation wound date of surgery must be > 30 days
  • 2 week run in period with less than 30% wound size reduction
  • University of Texas Grade 1A, 1B, 1C, 1D, 2A, 2B, 2C, or 2D (Appendix I)
  • Ulcer is ≥ 1cm2 and ≤ 20cm2 after debridement at start of run-in period
  • If more than one ulcer is present on the foot, only the largest is considered in the study (Index ulcer)
  • Index ulcer must be ≥ 1cm away from any other ulcers present on the foot
  • Adequate perfusion with ABI > 0.7 And TcpO2 > 30mmHg OR skin perfusion > 30mmHG OR Toe pressure > 30mmHg OR Duplex with biphasic waveforms below the knee
  • No planned revascularization procedure or vascular surgery within the last/next 30 days
  • Subject and/or caregiver are willing and able to comply with all specified care and visit requirements
  • Subject has a reasonable expectation of completing the study; according to the Investigator's clinical judgment

Exclusion Criteria:

  • Evidence of gangrene on any part of affected limb
  • Documented evidence of osteomyelitis on any part of affected limb
  • Index ulcer has exposed bone
  • Index ulcer exhibits signs of severe clinical infection that requires hospitalization or immediate surgical intervention
  • Active Charcot foot on the study limb
  • Subject participated in another investigational device, drug or biological trial within last 30 days
  • Uncontrolled diabetes: HbA1c > 12 %
  • Renal dialysis or creatinine > 2.5
  • Known immune insufficiency
  • Chronic steroid use or immunosuppressive agents within the last three (3) months or is anticipated to require them during the course of the study
  • Active treatment for malignancy (not specific to study limb)
  • Patient has a Deep Vein Thrombosis within the last 30 days
  • Subject has received growth factor therapy (e.g., autologous platelet-rich plasma gel, becaplermin, bilayered cell therapy, dermal substitute, extracellular matrix) within the screening period
  • Subject may not be pregnant at the time of treatment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02326337


Locations
Layout table for location information
United States, Arizona
Carl T. Hayden VA Medical Center
Phoenix, Arizona, United States, 85012
United States, California
NorthBay Center for Wounds
Vacaville, California, United States, 95687
United States, District of Columbia
Washington DC VA Medical Center
Washington, District of Columbia, United States, 20422
United States, Florida
The Research Center Inc.
Hialeah, Florida, United States, 33013
Advanced Research Institute of Miami
Miami, Florida, United States, 33012
Advanced Research Institute of Miami
Miami, Florida, United States, 33134
United States, Illinois
Edward Hines, Jr. VA Hospital
Chicago, Illinois, United States, 60141
United States, Nevada
Advanced Foot & Ankle Center
Las Vegas, Nevada, United States, 89119
United States, Virginia
Hunter Holmes McGuire VA Medical Center
Richmond, Virginia, United States, 23249
Salem VA Medical Center
Salem, Virginia, United States, 24153
France
Avicenne Hospital
Bobigny, France, 93000
Hospital Simone Veil
Eaubonne, France, 95600
Montpellier University Hospital
Montpellier, France, 34000
Germany
Städtisches Klinikum Dessau
Dessau, Germany, 06847
Luxembourg
Kirchberg Hospital
Luxembourg, Luxembourg, L-2540
United Kingdom
Northwick Park Hospital
Harrow, United Kingdom, HA1 3UJ
King's College Hospital
London, United Kingdom, SE5 9RS
Sponsors and Collaborators
AOTI Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Robert G Frykberg, DPM Carl T. Hayden VA Medical Center

Layout table for additonal information
Responsible Party: AOTI Ltd.
ClinicalTrials.gov Identifier: NCT02326337     History of Changes
Other Study ID Numbers: AOTI- TWO2DFU-01
First Posted: December 29, 2014    Key Record Dates
Last Update Posted: February 22, 2018
Last Verified: February 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Pediatric Postmarket Surveillance of a Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetic Foot
Foot Ulcer
Ulcer
Pathologic Processes
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Leg Ulcer
Skin Ulcer
Skin Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Diabetic Neuropathies
Foot Diseases